GlassScriptPhysician profile
David L Chengelis
NPI 1720069016
$57,367.01
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $23K · 2022: $5,603 · 2023: $1,098 · 2024: $371 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689 · Entertainment: $19.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.21 |
| Entertainment | $19.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $53,555.63 | 2019-2025 | Da Vinci Surgical System |
| Stryker Corporation | $869.88 | 2021 | |
| Medtronic, INC. | $850.66 | 2022-2024 | Signia |
| W. L. Gore & Associates, INC. | $508.05 | 2019-2023 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Apollo Endosurgery US INC | $473.10 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Reshape Lifesciences INC. | $320.20 | 2019-2023 | |
| Novo Nordisk INC | $133.10 | 2024 | Wegovy |
| Ethicon US, LLC | $105.73 | 2019 | |
| Boston Scientific Corporation | $75.09 | 2025 | General - Therapies |
| Heron Therapeutics, INC. | $71.79 | 2024-2025 | Zynrelef, Aponvie |
| Covidien LP | $70.31 | 2019 | |
| Medical Device Business Services, INC. | $58.05 | 2024 | Echelon Flex |
| Smith+Nephew, INC. | $53.68 | 2020 | |
| Amgen INC. | $42.63 | 2022-2023 | Repatha |
| Hologic Sales and Service, LLC | $39.73 | 2023 | Coolseal Generator |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $37.10 | 2023 | Accrufer |
| La Jolla Pharmaceutical Company | $33.28 | 2023 | Xerava |
| Acera Surgical, INC. | $25.87 | 2025 | Restrata Wound Matrix |
| Lucid Diagnostics INC. | $15.73 | 2023 | |
| Lilly USA, LLC | $14.37 | 2022 | |
| Davol INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chengelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.